Zurich Cantonal Bank
NTLA icon

Zurich Cantonal Bank’s Intellia Therapeutics NTLA Stock Holding History

Zurich Cantonal Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,178
Closed -$568K – 3181
2025
Q4 		$568K Buy
+63,178
New +$870K ﹤0.01% 1715

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Zurich Cantonal Bank's NTLA Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Intellia Therapeutics (NTLA) stake by 0.61% in Q2 2026, buying an estimated $5.92K and bringing the position to 69,747 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1453.

Zurich Cantonal Bank first reported a position in NTLA in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.08M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Zurich Cantonal Bank held 69,747 shares of Intellia Therapeutics worth $1.18M as of Q2 2026.
  • Zurich Cantonal Bank bought 423 Intellia Therapeutics shares in Q2 2026, an estimated $5.92K.
  • Intellia Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1453 holding.
  • Zurich Cantonal Bank first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Zurich Cantonal Bank's Intellia Therapeutics position peaked at $2.08M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.